As GLP-1 use grows, clinical trials suggest semaglutide may reduce alcohol cravings and drinks per occasion, putting greater pressure on the automatic second cocktail.

getty

How GLP-1 Drugs Could Change The Way Americans Order Drinks

With 11% of U.S. adults now using GLP-1 medications for weight loss, clinical trials suggest semaglutide may reduce alcohol cravings. The spirits industry is watching the second round.

What happens to the spirits business when a medication makes the next cocktail easier to refuse?

Meg Johnston noticed the change soon after she began taking semaglutide.

Johnston, a Washington, D.C., real estate agent, had gained weight during the pandemic. She was also drinking more than she wanted. After starting the medication, alcohol lost some of its appeal.

“Alcohol just doesn’t sound as appetizing,” Johnston told NPR. She began going entire days without drinking and said her tolerance had fallen.

Her account is personal, not clinical proof. New research is beginning to document a similar response among people with alcohol use disorder. Some participants taking semaglutide continued to drink, but consumed less when they did.

For bars and restaurants, the commercial consequence may not be an empty dining room. It could be the second cocktail that never reaches the check.

GLP-1 Use Has Become A Drinks Business Question

The number of consumers who could experience some change in alcohol cravings is no longer small.

In a recent Forbes article, Zachary Folk highlighted Gallup findings showing that 11% of U.S. adults currently use a GLP-1 medication for weight loss, up from 3% in 2024. Fifteen percent have used one at some point. Gallup surveyed 5,065 adults across every state and Washington, D.C. Awareness of GLP-1 weight-loss medications reached 91% in 2026, compared with 80% two years earlier. The drugs measured included semaglutide and tirzepatide, sold under names including Wegovy, Ozempic, Zepbound and Mounjaro.

Still, a medication used by roughly one in nine American adults can influence more than healthcare spending. Even a modest reduction in drinks per occasion could affect restaurant beverage checks and spirits brands that rely on frequent consumption.

Research Points To Fewer Drinks Per Occasion

The largest randomized trial to date was published in The Lancet in May 2026. The study enrolled 108 adults with obesity and moderate to severe alcohol use disorder. Participants received semaglutide or a placebo for 26 weeks. Both groups were also offered cognitive behavioral therapy.

Heavy drinking fell in both groups, but the decline was greater among participants receiving semaglutide. They also reported larger reductions in total monthly alcohol consumption, drinks per drinking day and alcohol cravings.

An earlier randomized trial published in JAMA Psychiatry offers a finding with particular relevance to the bar business. The nine-week study involved 48 adults with alcohol use disorder. Low-dose semaglutide reduced alcohol consumed during a laboratory session and lowered weekly cravings. It did not significantly change the number of drinking days. Participants taking the medication consumed fewer drinks on the days when they chose to drink.

The available evidence does not show that GLP-1 users will stop going to bars. It raises a different possibility.

They may still order the first drink and lose interest in the next one.

The Second Cocktail Is Already Harder To Sell

Restaurants were seeing more selective drinking before GLP-1 use reached its current scale.

Christa Cotton, CEO of New Orleans-based El Guapo, said guests increasingly pause before ordering another cocktail. They might choose one carefully made drink or follow it with an alcohol-free option.

“The second drink is where we see the biggest behavioral change,” Cotton said. “Guests may still want to participate, but they do not always want another alcoholic drink.”

Dan Simons, co-founder of Founding Farmers Restaurant Group, has noticed a similar pattern. Some customers begin with cocktails and continue the meal with alcohol-free drinks.

Simons said guests remain interested in celebrating with a beverage in hand. When they plan to have only one alcoholic drink, they are more likely to expect something premium.

Neither operator knows if an individual guest takes semaglutide. Restaurant employees do not ask customers about prescriptions, and the ordering data would not reveal them.

Their observations do show how lower drinking intensity appears on the dining-room floor. The guest arrives, participates and spends money. The lost revenue comes later, when another alcoholic drink no longer feels necessary.

Premiumization Does Not Erase Lost Volume

The spirits industry often answers falling volume with premiumization. The argument is simple. Consumers may drink less, but they will pay more for the drink they choose.

There is evidence of guests becoming more selective. It does not follow that a more expensive first cocktail fully replaces the revenue from a missing second one. A customer who previously ordered two cocktails but now orders one premium drink may still leave a smaller beverage check. The bar also loses the chance to sell a different spirit during the next round.

The pressure extends beyond wellness. Deloitte reported in May 2026 that four in ten U.S. consumers could be classified as value seekers. Compared with other respondents, they planned to spend between 20% and 40% less on alcohol at home and reduce alcohol spending at bars and nightclubs by more than half. The report identifies GLP-1 drugs as one influence among several, while arguing that consumers’ concerns about value may be more fundamental.

A premium cocktail therefore has to solve two problems. It must feel worth ordering, and its price must make sense to a guest who is already questioning the value of another round.

Calling every decline “less but better” risks turning a revenue problem into a flattering consumer narrative.

Some Spirits Categories Have More Protection Than Others

The spirits market was already uneven before the latest GLP-1 findings. U.S. spirits supplier sales fell 2.2% to $36.4 billion in 2025, according to the Distilled Spirits Council of the United States. Vodka sales declined 3%, while tequila and mezcal fell 4.1%. American whiskey was down 0.9%.

Premixed cocktails and spirits-based ready-to-drink products were the major exception. Sales reached $3.8 billion, an increase of 16.4%. DISCUS pointed to convenience, flavor and the availability of lower-alcohol products as factors supporting the category.

GLP-1 medications did not cause those category results. The figures do help identify which business models may have more room to adapt. Large brands dependent on repeated pours and habitual consumption may face greater exposure if people drink less during each occasion. A familiar vodka or value whiskey can be easier to skip when a guest no longer orders by routine.

Premium spirits may have some protection when the first drink is tied to discovery or a special occasion. They are not immune. One expensive pour still produces less volume than several.

Ready-to-drink cocktails may benefit from controlled portions and lower-alcohol formats. They also fit at-home occasions where consumers can purchase a single can without committing to a full bottle or a restaurant-priced cocktail. This is an inference from the category’s current growth, not evidence that GLP-1 users prefer RTDs.

Lower-ABV cocktails could also become more useful on menus. They let guests remain part of the drinking occasion while reducing the alcohol in each serving.The categories in the safest position will not necessarily be the most expensive. They will be the ones with a clear reason to exist after automatic consumption fades.

The Automatic Second Round Is No Longer Guaranteed

The evidence does not show that GLP-1 drugs are emptying America’s bars. It shows that semaglutide reduced heavy drinking and alcohol cravings in trials involving people with alcohol use disorder. It also shows that weight-loss use has grown enough to reach a meaningful share of American adults.

Johnston’s experience gives the research a human shape. Alcohol did not become forbidden. It became less compelling. That is a more complicated challenge for the spirits industry than abstinence. People will continue meeting for dinner. Many will still order a cocktail. They may choose a better spirit or spend more on the first drink.

For spirits brands and restaurant operators, the GLP-1 effect may not be the disappearance of drinking.

It may be the disappearance of drinking by default.